TBC1D30 Activators
The activators and modulators for TBC1 Domain Family Member 30 (TBC1D30) target various aspects of membrane trafficking and cellular signaling pathways. These compounds include both pharmacological agents and molecules that influence cellular transport and signaling. Brefeldin A and monensin are known to disrupt Golgi and intracellular trafficking, impacting TBC1D30's role in these processes. Forskolin, affecting cAMP levels, and rapamycin, an mTOR inhibitor, can modulate signaling pathways and cellular processes relevant to TBC1D30.
PI3K inhibitors like LY294002 and wortmannin, as well as NF-kB inhibitors, can impact signaling pathways that might indirectly influence TBC1D30. Ciliobrevin D, affecting dynein function, could provide insights into membrane trafficking processes involving TBC1D30. Chloroquine, affecting lysosomal function and autophagy, and TGF-beta receptor inhibitors might also have effects on TBC1D30. Wnt agonists and lithium chloride, which modulate Wnt and other signaling pathways, could influence TBC1D30's function. It is important to note that the influence of these compounds on TBC1D30 is indirect and based on their known actions in broader cellular contexts. The exact mechanisms by which they might influence TBC1D30 and their effectiveness in doing so would require further experimental validation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
An ionophore that disrupts intracellular ion balance and membrane trafficking, potentially affecting TBC1D30. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Activates adenylate cyclase, affecting cAMP levels and potentially influencing TBC1D30-related pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
As an mTOR inhibitor, rapamycin could affect cellular growth and membrane trafficking, potentially impacting TBC1D30. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Inhibiting the PI3K/Akt pathway could indirectly affect TBC1D30 through various signaling pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Inhibits PI3K, potentially impacting signaling pathways and membrane trafficking involving TBC1D30. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
NF-kB pathway modulation might have implications for TBC1D30's function. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Affects Wnt signaling and other pathways, potentially impacting TBC1D30. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $213.00 $359.00 | 3 | |
Modulating TGF-beta signaling could impact cellular processes relevant to TBC1D30. | ||||||